Disclosed are subpopulations of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes contain a portion of a population of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes can be CD36.sup.+ subpopulations or CD36.sup.− subpopulations. Disclosed are methods of isolating and of using the subpopulations of cardiomyocytes, particularly in cardiac disease modeling, drug screening, cardiotoxicity testing, and cardiac regeneration/repair.

The present disclosure relates to methods for improving myogenic differentiation capacity of a cell line or an immortalized cell line. For example, the present disclosure relates to methods of exposing an immortalized cell line (e.g., an immortalized fibroblast cell line) to culture media comprising signaling pathway agonists, antagonist, or a combination thereof in order to improve differentiation capacity. In another example, the present disclosure relates to methods of improving differentiation capacity of a cell line or an immortalized cell line where the method includes transforming an immortalized cell line with one or more myogenic regulatory factors and exposing the immortalized cell line to culture media comprising signaling pathway agonists, antagonists, or a combination thereof.

The present invention relates to a stable method for introducing at least one inducible cassette into a cell, and permitting controllable transcription from within that inducible cassette. The method may be used for any cell type, from any eukaryotic organism, but has a particular application in the introduction of inducible cassettes into pluripotent stem cells, such as animal or human pluripotent stem cells (hPSCs). The inducible cassette is controllably inserted in such a way to ensure that the genetic material it contains is not silenced or subject to negative influences from the insertion site, and transcription of the genetic material is controlled.

The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.

The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.

The present invention relates to a method for producing biodegradable fibers on the basis of a silane compound, said silane compound being crosslinked during production and, at least to some extent, an organic acid being incorporated into the forming crosslinked structure via covalent bonds and/or contributing to the crosslinking. The present invention also relates to the fibers that can be produced by the method according to the invention and to the use thereof.

The methods described herein are for conserving highly expanded cells that have functional properties such as potential for use in neotissue constructs. For example, highly expanded chondrocytes that can be used to construct neocartilage exhibiting functional properties similar to native articular cartilage. The methods and systems feature processes that form functional, human cartilage using cells that have been expanded to at least 1.5×10.sup.5 times or P3 or greater. This enables a large quantity of engineered cartilage implants to be produced from few cells.

A method to increase the efficiency of myotube generation and maturation from pluripotent stem cells comprising: (a) differentiating pluripotent stem cells to myogenic progenitors; and (b) terminally differentiating said myogenic progenitors from (a) into myotubes in the presence of at least one gamma secretase inhibitor, wherein myotube generation is increased in the presence of at least one gamma secretase inhibitor, as compared to differentiation in the absence of gamma secretase inhibitors.

Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue including continuously feeding the adipose tissue to the milling device; mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device by means of a multiplicity of blades of a rotor, wherein the blades are arranged in a spaced arrangement with respect to the overall direction of flow and the blades are moving about an axis of rotation, wherein the axis of rotation is provided essentially parallel to the overall direction of flow, continuously withdrawing the processed tissue comprising the separated cells from the milling device.

A composition according to an embodiment includes a first population of transformed mammalian cells with a transforming growth factor beta (TGF-β), the first population having a TGF-β expression level of 0.65 ng/10.sup.5 cells/24 hours or more, and a second population of mammalian cells which are not transformed with the transforming growth factor beta, the second population having an expression level of a thrombospondin 1 (TSP-1) expression level of 31 ng/10.sup.5 cells/24 hours or more.